Skip to main content
Journal cover image

Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.

Publication ,  Journal Article
Raymond, E; Kulke, MH; Qin, S; Yu, X; Schenker, M; Cubillo, A; Lou, W; Tomasek, J; Thiis-Evensen, E; Xu, J-M; Croitoru, AE; Khasraw, M ...
Published in: Neuroendocrinology
2018

BACKGROUND: In a phase III study, sunitinib led to a significant increase in progression-free survival (PFS) versus placebo in patients with pancreatic neuroendocrine tumours (panNETs). This study was a post-marketing commitment to support the phase III data. METHODS: In this ongoing, open-label, phase IV trial (NCT01525550), patients with progressive, advanced unresectable/metastatic, well-differentiated panNETs received continuous sunitinib 37.5 mg once daily. Eligibility criteria were similar to those of the phase III study. The primary endpoint was investigator-assessed PFS per Response Evaluation Criteria in Solid Tumours v1.0 (RECIST). Other endpoints included PFS per Choi criteria, overall survival (OS), objective response rate (ORR), and adverse events (AEs). RESULTS: Sixty-one treatment-naive and 45 previously treated patients received sunitinib. By March 19, 2016, 82 (77%) patients had discontinued treatment, mainly due to disease progression. Median treatment duration was 11.7 months. Investigator-assessed median PFS per RECIST (95% confidence interval [CI]) was 13.2 months (10.9-16.7): 13.2 (7.4-16.8) and 13.0 (9.2-20.4) in treatment-naive and previously treated patients, respectively. ORR (95% CI) per RECIST was 24.5% (16.7-33.8) in the total population: 21.3% (11.9-33.7) in treatment-naive and 28.9% (16.4-44.3) in previously treated patients. Median OS, although not yet mature, was 37.8 months (95% CI, 33.0-not estimable). The most common treatment-related AEs were neutropenia (53.8%), diarrhoea (46.2%), and leukopenia (43.4%). CONCLUSIONS: This phase IV trial confirms sunitinib as an efficacious and safe treatment option in patients with advanced/metastatic, well-differentiated, unresectable panNETs, and supports the phase III study outcomes. AEs were consistent with the known safety profile of sunitinib.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Neuroendocrinology

DOI

EISSN

1423-0194

Publication Date

2018

Volume

107

Issue

3

Start / End Page

237 / 245

Location

Switzerland

Related Subject Headings

  • Survival Rate
  • Sunitinib
  • Pancreatic Neoplasms
  • Neuroendocrine Tumors
  • Middle Aged
  • Male
  • Humans
  • Female
  • Endocrinology & Metabolism
  • Disease-Free Survival
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Raymond, E., Kulke, M. H., Qin, S., Yu, X., Schenker, M., Cubillo, A., … Fazio, N. (2018). Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. Neuroendocrinology, 107(3), 237–245. https://doi.org/10.1159/000491999
Raymond, Eric, Matthew H. Kulke, Shukui Qin, Xianjun Yu, Michael Schenker, Antonio Cubillo, Wenhui Lou, et al. “Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.Neuroendocrinology 107, no. 3 (2018): 237–45. https://doi.org/10.1159/000491999.
Raymond E, Kulke MH, Qin S, Yu X, Schenker M, Cubillo A, et al. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. Neuroendocrinology. 2018;107(3):237–45.
Raymond, Eric, et al. “Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.Neuroendocrinology, vol. 107, no. 3, 2018, pp. 237–45. Pubmed, doi:10.1159/000491999.
Raymond E, Kulke MH, Qin S, Yu X, Schenker M, Cubillo A, Lou W, Tomasek J, Thiis-Evensen E, Xu J-M, Croitoru AE, Khasraw M, Sedlackova E, Borbath I, Ruff P, Oberstein PE, Ito T, Jia L, Hammel P, Shen L, Shrikhande SV, Shen Y, Sufliarsky J, Khan GN, Morizane C, Galdy S, Khosravan R, Fernandez KC, Rosbrook B, Fazio N. Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. Neuroendocrinology. 2018;107(3):237–245.
Journal cover image

Published In

Neuroendocrinology

DOI

EISSN

1423-0194

Publication Date

2018

Volume

107

Issue

3

Start / End Page

237 / 245

Location

Switzerland

Related Subject Headings

  • Survival Rate
  • Sunitinib
  • Pancreatic Neoplasms
  • Neuroendocrine Tumors
  • Middle Aged
  • Male
  • Humans
  • Female
  • Endocrinology & Metabolism
  • Disease-Free Survival